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Ankylosing	spondylitis	is	a	common,	highly	heritable	inflammatory	arthritis	affecting	primarily	the	spine	and	pelvis.	In	addition	
to	HLA-B*27	alleles,	12	loci	have	previously	been	identified	that	are	associated	with	ankylosing	spondylitis	in	populations	
of	European	ancestry,	and	2	associated	loci	have	been	identified	in	Asians.	In	this	study,	we	used	the	Illumina	Immunochip	
microarray	to	perform	a	case-control	association	study	involving	10,619	individuals	with	ankylosing	spondylitis	(cases)	and	
15,145	controls.	We	identified	13	new	risk	loci	and	12	additional	ankylosing	spondylitis–associated	haplotypes	at	11	loci.		
Two	ankylosing	spondylitis–associated	regions	have	now	been	identified	encoding	four	aminopeptidases	that	are	involved	in	
peptide	processing	before	major	histocompatibility	complex	(MHC)	class	I	presentation.	Protective	variants	at	two	of	these	loci	
are	associated	both	with	reduced	aminopeptidase	function	and	with	MHC	class	I	cell	surface	expression.
Crohn’s disease and ulcerative colitis, along with several classic 
autoimmune diseases, were used in the chip design, making it a power­
ful platform for studies of pleiotropic genetic effects in these related 
diseases. In this study, we aimed to identify new associations with 
ankylosing spondylitis and to dissect and refine the boundaries of 
known associated loci by performing a dense SNP genotyping study 
in 10,619 cases and 15,145 controls of European, East Asian and Latin 
American ancestry using the Immunochip.
RESULTS
Primary	association	findings
After all sample quality control filters, the European cohort consisted 
of 9,069 cases and 13,578 controls, and the East Asian cohort con­
sisted of 1,550 cases and 1,567 controls. The genomic inflation factor 
(λ) calculated using 1,922 SNPs included on the Immunochip from 
studies of reading and writing ability, psychosis and schizophrenia 
was 1.047 (λ1000 for an equivalent study of 1,000 cases and 1,000 con­
trols = 1.0285), indicating minimal evidence of residual population 
stratification in the overall data set (quantile­quantile plots are pre­
sented in Supplementary Fig. 1).
Association at genome­wide significance (P < 5 × 10−8) was observed 
for 25 loci, including the MHC (Table 1 and Supplementary Fig. 2; 
genomic control–corrected results are shown in Supplementary 
Table 1). Suggestive association (P < 5 × 10−7) was observed at six 
additional loci (Supplementary Table 2). As with all GWAS, there is 
uncertainty as to the genes contributing to association at specific loci. 
At previously reported loci, association (P < 5 × 10−8) was seen with 
the most strongly associated previously reported SNPs at CARD9, 
ERAP1, IL12B, IL23R, KIF21B, RUNX3, NPEPPS­TBKBP1­TBX21, 
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Inflammatory arthritis in ankylosing spondylitis causes pain and stiff­
ness and progressively leads to new bone formation and ankylosis 
(fusion) of affected joints. It affects 0.55% of populations of European 
ancestry (herein termed Europeans)1 and 0.23% of Chinese2, but is 
uncommon in Africans and Japanese, mostly owing to the low preva­
lence in these ancestry groups of HLA-B*27, the major genetic variant 
associated with ankylosing spondylitis. Whereas effective treatments 
are available that suppress inflammation and improve symptoms, 
there are not yet any treatments that have been shown to robustly 
slow the rate of ankylosis or induce disease remission.
Ankylosing spondylitis is highly familial (sibling recurrence risk ratio 
of >52)3 and heritable (h2 > 90%)4. It is two to three times more preva­
lent in men than in women, and men tend to be more severely affected. 
More than 80% of cases are positive for the HLA-B*27 allele, but only a 
minority of HLA-B*27 carriers develop ankylosing spondylitis (1–5%). 
The low proportion of HLA-B*27 carriers who develop ankylosing 
spondylitis reflects the fact that numerous other non–HLA-B*27  
variants are likely to influence disease susceptibility3. In addition to 
HLA-B*27, 12 loci have previously been confirmed to be associated 
with ankylosing spondylitis in Europeans (ANTXR2, CARD9, ERAP1, 
IL12B, IL23R, KIF21B, PTGER4, RUNX3, TBKBP1, TNFRSF1A and 
chromosomes 2p15 and 21q22)5–7, and 2 loci have recently been 
reported in Han Chinese (HAPLN1­EDIL3 and ANO6)8.
The Immunochip Consortium has developed a custom microarray 
SNP genotyping chip (the Immunochip), the design of which has 
been informed by available genome­wide association study (GWAS) 
and deep sequencing data from various autoimmune and inflamma­
tory diseases to provide a cost­effective platform for immunogenetic 
studies9,10. Genetic data from ankylosing spondylitis, psoriasis, 
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TNFRSF1A and chromosomes 2p15 and 21q22 (Table 1). At PTGER4, 
the previously associated SNP (rs10440635) also showed moderate 
association in the current study (P = 3.0 × 10−5; imputed). No SNPs 
at the ANTXR2 locus were included on the Immunochip.
We observed little evidence of association with the two previously 
reported loci in Han Chinese, either in Europeans, East Asians 
(Chinese, Taiwanese and Koreans) or in the combined data set 
(P > 0.05)8. To increase power for these variants, we genotyped a total 
of 2,998 East Asian cases and 5,547 East Asian controls. No associa­
tion was seen (P > 0.05) for either rs4552569 (chromosome 5q14, 
between HAPLN1 and EDIL3) or rs17095830 (chromosome 12q12, 
ANO6) (Supplementary Table 3). rs4552569 showed only nominal 
significance in Europeans (P = 0.02). rs17095830 was not directly 
typed on the Immunochip, but, in a previous GWAS6, no association 
was observed with this SNP (P > 0.1).
Genome­wide significance was seen at 13 loci not previously known to 
be associated with ankylosing spondylitis (Table 1). The strongest asso­
ciation at each locus was with a common variant (minor allele frequency 
(MAF) > 5%), but several associations were also seen with rare variants 
(MAF < 1%) at these loci, including in the genes CARD9, IL23R, LNPEP 
and TYK2. Both rare variants in IL23R were nonsynonymous coding 
variants, whereas the CARD9, TYK2 and LNPEP variants were located 
at exon­intron boundaries and were predicted to influence splicing.
In total, 24.4% of the heritability of ankylosing spondylitis 
is now explained: 4.3% from loci other than HLA-B and 20.1% due 
to HLA-B*27 itself.
IL-23	pathway	genes
Genetic studies provided the first evidence that interleukin (IL)­23 
is involved in the pathogenesis of ankylosing spondylitis, and vari­
ants in several genes involved in the IL­23 proinflammatory cytokine 
pathway have been shown to be associated with the disease. This study 
adds to that list, with loci containing TYK2, IL6R and IL27 achieving 
genome­wide significance.
IL­6 signaling through IL­6R has diverse proinflammatory effects. 
rs4129267, the most strongly associated IL6R SNP in this study, is also 
associated with asthma11 but with the opposite direction of associa­
tion to ankylosing spondylitis. The allele associated with risk of anky­
losing spondylitis at this SNP is strongly associated with lower serum 
concentrations of the soluble form of the IL­6 receptor (sIL­6R), with 
each allele associated with a 1.4­fold variation in serum IL­6R conc­
netrations12. We found that sIL­6R concentrations varied strongly by 
rs4129267 genotype, both overall and separately, in cases and controls 
(Fig. 1). Overall, homozygous carriers of the T allele at rs4129267 had 
sIL­6R concentrations 73% higher than homozygous carriers of the 
C allele (28.9 versus 16.7 ng/ml; P = 7.8 × 10−17). This SNP has previ­
ously been associated with serum C­reactive protein (CRP) concen­
trations at genome­wide significance; in the current study, serum CRP 
concentrations were 30% higher in cases homozygous for the T allele 
than in cases homozygous for the C allele (19.2 versus 14.8 mg/l).
At IL23R, we previously identified two independent disease­
 associated haplotypes6 tagged by rs11209026 and rs11209032. Here, 
after conditioning on rs11209026, the strongest association was with 
table 1 Non-MHc associations with ankylosing spondylitis susceptibility
SNP Chr. Positiona Nearby gene(s) Combined P
Risk/ 
non-risk 
allele
Combined  
OR
Europeans East Asians
RAF  
(case/control) OR P
RAF  
(case/control) OR P
Loci previously associated with ankylosing spondylitis at genome-wide significance
rs6600247 1p36 25177701 RUNX3 2.6 × 10−15 C/T 1.15 0.540/0.501 1.16 1.3 × 10−14 0.731/0.708 1.12 0.047
rs11209026 1p31 67478546 IL23R 2.0 × 10−27 G/A 1.62 0.959/0.934 1.65 6.0 × 10−28 1.000/1.000 NA NA
rs41299637 1q32 199144473 GPR25-KIF21B 1.9 × 10−15 T/G 1.19 0.757/0.715 1.20 7.0 × 10−16 0.999/0.998 1.05 0.42
rs6759298 2p15 62421949 Intergenic 4.9 × 10−47 C/G 1.29 0.447/0.378 1.31 3.6 × 10−41 0.437/0.374 1.28 1.6 × 10−6
rs12186979 5p13 40560617 PTGER4 4.3 × 10−6 G/A 1.08 0.516/0.498 1.09 5.4 × 10−6 0.202/0.191 1.06 0.26
rs30187 5q15 96150086 ERAP1 4.4 × 10−45 T/C 1.29 0.405/0.338 1.32 1.3 × 10−41 0.542/0.486 1.36 2.0 × 10−5
rs6871626 5q33 158759370 IL12B 3.1 × 10−8 A/C 1.10 0.360/0.337 1.12 6.0 × 10−8 0.324/0.310 1.08 0.17
rs1128905 9q34 138373660 CARD9 7.0 × 10−9 C/T 1.10 0.529/0.503 1.12 1.6 × 10−9 0.316/0.315 1.00 0.99
rs1860545 12p13 6317038 LTBR- 
TNFRSF1A
2.8 × 10−10 C/T 1.13 0.634/0.605 1.13 8.3 × 10−10 0.862/0.851 1.07 0.21
rs9901869 17q21 42930205 NPEPPS- 
TBKBP1-TBX21
6.0 × 10−15 A/G 1.14 0.548/0.516 1.15 2.3 × 10−12 0.667/0.626 1.18 0.002
rs2836883 21q22 39388614 Intergenic 6.5 × 10−17 G/A 1.18 0.768/0.734 1.19 1.8 × 10−14 0.817/0.774 1.30 3.5 × 10−5
New loci associated with ankylosing spondylitis at genome-wide significance
rs4129267 1q21 152692888 IL6R 3.4 × 10−13 C/T 1.14 0.635/0.592 1.18 2.1 × 10−15 0.619/0.620 1.00 0.99
rs1801274 1q23 159746369 FCGR2A 1.4 × 10−9 T/C 1.11 0.487/0.476 1.12 9.9 × 10−10 0.706/0.698 1.04 0.46
rs12615545 2q31 181756697 UBE2E3 1.0 × 10−9 C/T 1.12 0.451/0.421 1.11 2.3 × 10−7 0.710/0.673 1.20 8.5 × 10−4
rs4676410 2q37 241212412 GPR35 9.9 × 10−9 T/C 1.13 0.232/0.209 1.13 2.1 × 10−7 0.346/0.312 1.15 8.4 × 10−3
rs17765610 6q15 90722494 BACH2 5.3 × 10−8 G/A 1.15 0.131/0.118 1.17 3.3 × 10−8 0.017/0.018 1.00 0.96
rs1250550 10q22 80730323 ZMIZ1 1.5 × 10−9 G/T 1.11 0.678/0.652 1.11 5.8 × 10−7 0.583/0.539 1.20 3.9 × 10−4
rs11190133 10q24 101268715 NKX2-3 4.9 × 10−14 C/T 1.15 0.737/0.707 1.18 1.7 × 10−14 0.629/0.617 1.10 0.30
rs11065898 12q24 110346958 SH2B3 4.7 × 10−8 T/C 1.11 0.237/0.216 1.13 1.7 × 10−7 0.348/0.329 1.10 0.082
rs11624293 14q31 87558574 GPR65 1.5 × 10−10 C/T 1.20 0.106/0.087 1.23 1.8 × 10−10 0.158/0.145 1.11 0.14
imm_16_
28525386
16p11 28525386 IL27-SULT1A1 2.6 × 10−9 A/G 1.11 0.421/0.393 1.11 1.4 × 10−7 0.258/0.232 1.16 0.012
rs2531875 17q11 23172294 NOS2 1.2 × 10−10 G/T 1.12 0.396/0.367 1.12 1.3 × 10−8 0.296/0.256 1.22 4.6 × 10−4
rs35164067 19p13 10386181 TYK2 3.4 × 10−10 G/A 1.14 0.819/0.796 1.16 6.5 × 10−9 0.574/0.549 1.11 0.039
rs7282490 21q22 44440169 ICOSLG 6.2 × 10−9 G/A 1.11 0.411/0.390 1.10 1.4 × 10−6 0.581/0.543 1.18 1.3 × 10−3
Locus plots for reported associations are shown in supplementary Figure 5. Chr., chromosome; RAF, risk allele frequency; NA, not available.
aNCBI Build 36 human genome coordinates.
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rs12141575 (odds ratio (OR) = 1.15; P = 9.4 × 10−11); this SNP is in 
strong linkage disequilibrium (LD) with rs11209032 (r2 = 0.993) and 
also with rs1495965, which has been reported to be associated with 
Behçet’s disease13,14. Behçet’s disease is complicated by sacroiliitis 
resembling ankylosing spondylitis in up to 10% of cases15.
Six loci showed suggestive association (5 × 10−8 < P < 5 × 10−7), 
including a region on chromosome 2q11 encoding IL1R2 and IL1R1. 
Conditional analyses showed that there were two separate signals at 
this locus (Table 2), one in each gene. Both genes encode receptors for 
the cytokine IL­1, which, among diverse proinflammatory functions, 
also promotes T helper 17 (TH17) lymphocyte differentiation.
Aminopeptidase	genes
We previously identified a strong association between ERAP1 
and ankylosing spondylitis5 that is restricted to HLA-B*27– 
positive disease6. This observation was replicated here (Table 3 and 
Supplementary Figs. 3 and 4), with strong interaction observed 
in the European cases between HLA-B*27 and both independently 
associated ERAP1 haplotype–tagging SNPs (rs30187: β = 0.390, 
P = 2.9 × 10−11; rs10045403: β = −0.282, P = 9.3 × 10−6; Supplementary 
Table 4). We observed no evidence of epistasis between HLA-B*27 and 
rs30187 (or other SNPs in ERAP1) in the East Asian samples, probably 
because of inadequate statistical power. In this analysis, we had 35% 
power to detect an association at a significance level of P < 0.05 with 
the observed allele frequency of rs30187 in controls and the effect size 
observed in the overall analysis. The low power to detect a major effect 
at rs30187 in HLA-B*27–positive East Asian samples suggests that the 
power to detect an interaction would be quite small. The observed 
OR (95% confidence interval (CI)) in HLA-B*27–positive subjects 
at rs30187 was 0.73 (0.53–1.03) compared to 1.20 (0.89–1.61) in 
HLA-B*27–negative subjects. Although these analyses did not detect 
significant interaction (P > 0.05), they are consistent with an interac­
tion between rs30187 and HLA-B*27, where rs30187 is only associated 
in HLA-B*27–positive disease. This finding warrants further explora­
tion with larger sample sizes in East Asian populations.
LNPEP and ERAP2 are both members of the endoplasmic reticulum 
(ER) aminopeptidase family and have substantial sequence homology 
with ERAP1. They are both encoded on chromosome 5q15, imme­
diately centromeric to the ERAP1 locus. A previous study, which did 
not control for the association of ERAP1 with ankylosing spondylitis, 
observed no association of an ERAP2 loss­of­function variant with 
ankylosing spondylitis16. Other studies have identified associations 
with ERAP2 but have not dissected them from the known associations 
of ERAP1 SNPs5,17. Here, controlling for the association of ERAP1 with 
ankylosing spondylitis, two functionally important SNPs in ERAP2 
were found to be associated with ankylosing spondylitis: rs2549782, 
which leads to a change in ERAP2 catalytic activity18, and rs2248374, 
where the protective G allele causes complete loss of ERAP2 mRNA 
and absence of ERAP2 protein19. In the European samples, control­
ling for the association with ERAP1, we identified SNPs in ERAP2 
and LNPEP that were associated with ankylosing spondylitis (lead 
SNP, rs2910686: OR = 1.2, P = 4.5 × 10−17; Supplementary Fig. 3b). 
Because the association of ERAP1 variants was restricted to HLA-
B*27–positive ankylosing spondylitis, analyzing ERAP2 and LNPEP 
SNPs in HLA-B*27–negative cases and controls produced simi­
lar results to analyses of the combined (HLA-B*27–positive and 
HLA-B*27–negative) cases and controls when the association with 
ERAP1 was controlled for. Thus, we observed association with ERAP2 
SNPs in HLA-B*27–negative ankylosing spondylitis cases (rs2910686: 
OR = 1.19, P = 2.13 × 10−5). To investigate the possibility that this 
finding might be an artifact caused by the strong LD between the 
ERAP2 locus and HLA-B*27 in cases, we tested association at this 
locus in a multivariate analysis, controlling in the one analysis for 
association of the two ankylosing spondylitis–associated ERAP1 hap­
lotypes (tagged by rs30187 and rs10045403), their interaction with 
HLA-B*27 and HLA-B*27 itself. In this analysis, association with 
rs2910686 was robust (P = 6.6 × 10−8), suggesting that ERAP2­LNPEP 
is independently associated with ankylosing spondylitis. Haplotype 
counts for rs2910686 and rs30187 in both HLA-B*27–positive and 
HLA-B*27–negative cases are shown in Table 3.
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Figure 1 IL6R polymorphism alters IL-6R serum concentrations.  
IL-6R concentrations were determined in cases and controls who were 
homozygous for either the T or C allele at the rs4129267 SNP. In both 
cases and controls, individuals homozygous for the C allele showed 
significantly lower concentrations of circulating IL-6R. ***P < 0.0001; 
NS, not significant. Bars represent mean ± s.e.m.
table 2 secondary signals in europeans at loci known to be associated with ankylosing spondylitis
Chr. SNP Position Nearby gene(s)
Risk/non-risk 
allele Conditional SNP P OR
RAF  
(case/control)
LD (r2/D ′) with  
conditional SNP
1p31 rs12141575 67520024 IL23R A/G rs11209026 9.4 × 10−11 1.15 0.370/0.330 0.034/0.983
1q23 rs2039415 159121069 FCGR2A C/T rs1801274 7.4 × 10−5 1.09 0.702/0.682 0.002/0.062
2q12 rs2192752 102135805 IL1R2-IL1R1 C/A rs4851529 4.1 × 10−6 1.11 0.239/0.222 0.007/0.192
5q15 rs10045403 96173489 ERAP1-ERAP2 A/G rs30187 and rs2910686 5.8 × 10−14 1.20 0.783/0.730
0.178/0.958
0.091/0.429
5q15 rs2910686 96278345 ERAP1-ERAP2 C/T rs30187 4.5 × 10−17 1.17 0.450/0.440 0.153/0.617
5q33 rs6556416 158751323 IL12B C/A rs6871626 4.4 × 10−6 1.11 0.704/0.675 0.048/0.443
6q15 rs639575 91047852 BACH2 A/T rs17765610 8.6 × 10−5 1.08 0.624/0.609 0.000/0.042
12p13 rs7954567 6361386 LTBR-TNFRSF1A A/G rs1860545 1.2 × 10−7 1.11 0.363/0.341 0.002/0.068
16p11 rs35448675 28236248 IL27-SULT1A1 A/G imm_16_28525386 2.4 × 10−4 1.24 0.007/0.006 0.003/0.955
17q11 rs2297518 23120724 NOS2 A/G rs2531875 6.3 × 10−7 1.13 0.212/0.190 0.000/0.048
19p13 rs6511701 10486067 TYK2 A/C rs35164067 1.4 × 10−4 1.10 0.220/0.218 0.162/0.419
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In addition to these ERAP1 and ERAP2 associations, we observed 
genome­wide significant association of SNPs on chromosome 17q21 
around the gene NPEPPS, which encodes puromycin­sensitive ami­
nopeptidase (rs9901869: OR = 1.14, P = 6.0 × 10−15) (Supplementary 
Fig. 5). The NPEPPS protein localizes to the cytoplasm and is thought 
to be involved in processing proteasome­derived peptides before their 
transport to the endoplasmic reticulum and presentation by human 
leukocyte antigen (HLA) class I molecules20. Association had previ­
ously been reported at this locus and was ascribed to TBKBP1 or 
TBX21. Here SNPs mapping to NPEPPS and TBX21 were independ­
ently associated with ankylosing spondylitis, and conditional analysis 
suggested that there are at least two independent signals at this locus. 
When conditioning on rs9901869, SNP rs11657479 in the 3′ UTR of 
TBX21 remained significantly associated with ankylosing spondylitis 
(OR = 1.09; P = 1.8 × 10−3). The data did not allow us to determine 
whether TBKBP1 or TBX21 was primarily associated with ankylos­
ing spondylitis, but both represent attractive candidates. TBKBP1 is 
a component of the tumor necrosis factor (TNF) signaling pathway, 
and TBX21 is a transcription factor that influences the differentiation 
of T helper 1 (TH1) and natural killer (NK) cells21.
Genes	influencing	lymphocyte	activation	and	differentiation
It has recently been shown that cell type–specific trimethylation of his­
tone H3 at lysine 4 (H3K4me3) chromatin marks can inform the fine 
mapping of associated SNPs to identify causal variation22. We therefore 
tested all ankylosing spondylitis–associated SNPs against H3K4me3 
chromatin marks in different cell lines from the Encyclopedia of DNA 
Elements (ENCODE) Project23. This analysis showed a strong enrich­
ment of disease­associated SNPs associated with H3K4me3 chromatin 
marks in cells of immune origin (Supplementary Fig. 6).
Because of this association and taking into account the likely 
pathogenic role of T lymphocytes in ankylosing spondylitis and the 
involvement of several genes associated with ankylosing spondylitis 
in T­lymphocyte differentiation, we tested association of the SNPs 
for ankylosing spondylitis with CD4+ and CD8+ T cell counts in a 
previously published GWAS data set24. Association (P < 0.005) was 
seen between CD8+ lymphocyte counts and ankylosing spondylitis– 
associated SNPs in the loci harboring the genes IL7R, RUNX3 and 
ZMIZ1 (Supplementary Table 5). Association was also observed 
between SNPs in EOMES and CD8+ lymphocyte counts, but these 
were not the same EOMES SNPs that were associated with ankylosing 
spondylitis. We also showed association of the genes SH2B3 and 
BACH2 with both ankylosing spondylitis and CD4+ lymphocyte 
counts (Supplementary Table 5). We previously showed that CD8+ 
lymphocyte counts are lower in ankylosing spondylitis cases than in 
healthy age­ and sex­matched controls6. In contrast, in this study, 
we found that ankylosing spondylitis cases not on biological therapy 
had similar CD4+ lymphocyte counts as age­matched controls 
(Supplementary Fig. 7).
HLA	Region
After SNP imputation in the MHC region, rs116488202 was found 
to tag HLA-B*27 more accurately in both Europeans and Asians than 
our previously reported tagging SNP rs4349859 and also rs13202464, 
reported to tag HLA-B*27 in Asian populations8 (Supplementary 
Table 6). The expected strong association was observed with 
HLA-B*27 (OR = 46; P < 1 × 10−100) (Supplementary Fig. 8). 
Risk of ankylosing spondylitis was further increased in HLA-B*27  
homozygotes; HLA-B*27 homozygosity was more prevalent in 
HLA-B*27–positive cases than in HLA-B*27–positive controls 
(OR = 2.07; P = 0.0025).
Controlling for association with HLA-B*27, there was residual 
signal with SNPs near HLA-A and HLA-B (Fig. 2). The residual 
signal at HLA-B may reflect either imperfect HLA-B*27 tagging by 
rs116488202 or association of other HLA-B alleles with ankylosing 
spondylitis. No other individual non–HLA-B*27 allele was associated 
with ankylosing spondylitis, although this may represent imperfect 
HLA-B imputation using single SNPs.
The most strongly associated SNP near HLA-A, rs2394250, tags the 
classical allele HLA-A*0201 (Supplementary Table 7). Association 
of the HLA-A*0201 allele was independent of HLA-B*27 genotype, 
present in both HLA-B*27–positive (OR = 1.21, P = 6.5 × 10−12; 
conditioning on rs116488202) and HLA-B*27–negative (OR = 1.36, 
P = 3.2 × 10−13) disease (Supplementary Table 7b). No significant 
correlation was noted between HLA-B*27 and SNPs tagging 
table 3 Association analysis of rs30187 and rs2910686 haplotypes in samples positive and negative for HLA-B*27
Sample SNP (ERAP1)
Haplotype counts  
(controls/cases) SNP (ERAP2) Haplotype
Haplotype counts  
(controls/cases) OR (95% CI)
rs2910686  
association P value
HLA-B*27 positive
rs30187[T] 790/5,641 rs2910686[T] TT 662/4,595 1.18 (0.96–1.44) 0.12
rs2910686[C] TC 128/1,046
rs30187[C] 1,580/7,979 rs2910686[T] CT 646/2,923 1.20 (1.07–1.34) 1.5 × 10−3
rs2910686[C] CC 934/5,056
HLA-B*27 negative
rs30187[T] 8,298/763 rs2910686[T] TT 6,902/629 1.05 (0.87–1.28) 0.64
rs2910686[C] TC 1,396/134
rs30187[C] 16,240/1,515 rs2910686[T] CT 6,842/548 1.28 (1.15–1.43) 7.7 × 10−6
rs2910686[C] CC 9,398/967
Association was assessed by 1-degree-of-freedom χ2 test.
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Figure 2 Ankylosing spondylitis susceptibility associations in the MHC 
region conditioning on the HLA-B*27–tagging SNP rs116488202 and 
further conditioning on the HLA-A*02–tagging SNP rs2394250.  
The 85-kb gap between positions 32,465 kb and 32,550 kb corresponds 
to an assembly correction between NCBI Genome Builds 36 and 37 of the 
human genome.
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HLA-A*0201 (r2 < 0.01), and, thus, this association is not a manifesta­
tion of LD with HLA-B*27.
Overlap	with	other	immune-mediated	diseases
Considering the loci associated with ankylosing spondylitis in this 
study, we found substantial overlap with other immune­mediated 
diseases (Fig. 3 and Supplementary Table 8), notably, inflammatory 
bowel disease (either Crohn’s disease or ulcerative colitis) and celiac 
disease. Ankylosing spondylitis–associated loci were associated with 
the same SNP in the same direction of association at 12 loci shared 
with Crohn’s disease, at 11 loci shared with ulcerative colitis and at 
6 of 7 loci shared with celiac disease. Overlap of associated loci with 
other diseases was not as marked, including for rheumatoid arthritis 
(one concordant, one discordant), psoriasis (two concordant), multi­
ple sclerosis (three concordant, three discordant) and type 1 diabetes 
(two concordant, two discordant).
Refinement	of	disease	associations	and	secondary	signals
In the design of the Immunochip, eight loci already known to be 
associated with ankylosing spondylitis were selected for fine mapping. 
Compared with available ankylosing spondylitis GWAS data, the cur­
rent study had greater marker density at these loci and larger sample 
size (from 3,023 cases and 8,779 controls to 10,619 cases and 15,145 
controls). Nonetheless, for most loci studied, the disease­associated 
region was not substantially narrowed; less than 10% narrowing of the 
region was observed for four of the eight loci that were fine mapped 
(Supplementary Table 9). This suggests that, for many loci associated 
with common variants, the extent of LD at the locus will be too great 
to permit substantial refinement of the locus using sample sizes and 
marker densities of the magnitude employed here.
Two or more independent signals were identified at 12 of 
the 25 genome­wide significant loci (P < 5 × 10−4; Table 2 and 
Supplementary Fig. 9), including 1 locus (ERAP1 on chromosome 
5q15) with 3 associated haplotypes (Supplementary Fig. 3). This is 
a similar proportion to that found in celiac disease (13 of 36 loci)10. 
Taken together, these secondary signals contribute 0.75% of the herit­
ability of ankylosing spondylitis (Supplementary Table 10).
Rare	variants
Because of the likelihood of population stratification affecting rare 
variant associations, rare variant associations (MAF < 1%) were only 
tested on a reduced sample subset of indi­
viduals from the UK (7,447 cases and 11,479 
controls). Considering loci with common 
variant associations achieving genome­wide 
significance, we identified six that harbored 
rare SNPs that were disease associated (P < 
5 × 10−3; Supplementary Table 11). These 
associations remained significant after con­
ditioning on the common variants, and vari­
ants at three loci (IL23R, TYK2 and KEAP1) 
remained significant after controlling for the number of variants 
studied per locus. Four loci had exonic rare variant associations in 
the absence of a common variant association (P < 5 × 10−5) (KLKB1, 
RAD50, PRDM1 and DYRK4; Supplementary Table 11b). The rare 
variant with the largest effect was a predicted splice­site variant in 
TYK2 (rs280518: OR = 7.7, P = 0.002).
Comparisons	across	ancestry	groups
The power of our East Asian case­control cohort was much lower than 
for our European cohort; nonetheless, at least nominal association 
(P < 0.01) was detected in East Asians at 13 of the 23 loci for which 
we identified associations at genome­wide significance in the overall 
data set (Table 1).
At some loci, association was seen in both East Asians and 
Europeans but with different SNPs. At IL23R, the primary associ­
ated variant in Europeans, rs11209026, was not polymorphic in East 
Asians, as we and others have previously reported25. However, asso­
ciation was observed at IL23R with a low­frequency nonsynonymous 
SNP in East Asians (rs76418789: p.Gly149Arg, OR = 1.5, P = 8.2 × 
10−4). The minor, protective allele was predicted to be deleterious by 
both SIFT26 and PolyPhen analysis27. The same SNP was also nomi­
nally associated with ankylosing spondylitis in Europeans (P = 0.01). 
The MAF of rs76418789 was ~10 times greater in East Asians than in 
Europeans (East Asians, 3.7%; Europeans, 0.34%). Of the other loci 
associated with ankylosing spondylitis in Europeans but not in East 
Asians, only at BACH2 was the key associated variant present at a 
much lower frequency in East Asians (rs17765610; MAF of 11.8% in 
Europeans and 1.8% in East Asians), suggesting that, at most loci with 
discordant association between ancestry groups, this was not due to 
differences in the population frequency of the associated SNP.
At PTGER4, association in Europeans peaked 155 kb 5′ of the gene 
(peak associated SNP, rs12186979: OR = 1.1, P = 5.4 × 10−6), whereas 
the peak of association in East Asians was in intron 2 of the gene 
(rs13354346: OR = 1.3, P = 1.5 × 10−5) (Supplementary Fig. 5).
DISCUSSION
This study confirmed the association of 12 of the 13 previously reported 
loci associated with ankylosing spondylitis in Europeans and identified 
13 additional loci at genome­wide significance. We found no inde­
pendent support for two loci previously reported to be associated with 
ankylosing spondylitis in Han Chinese, suggesting that the original 
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associations of these loci may have been false positives. Additional 
associated haplotypes were identified at 13 loci, increasing the total 
number of distinct ankylosing spondylitis associations to 43.
These findings highlight the role of some major biological pathways 
in the pathogenesis of ankylosing spondylitis, including the IL­23 
pathway, gut immunity, T­lymphocyte differentiation or activation, 
and peptide processing before HLA class I presentation.
We identified three new ankylosing spondylitis–associated genes 
(TYK2, IL27 and IL6R) with known effects on the IL­23 pathway. 
TYK2 is a member of the Janus kinase family of intracellular signaling 
proteins and is involved in signal transduction from IL­23R, as well 
as other cytokine receptors, including those in interferon (IFN)­α, 
IFN­β, IL­6, IL­10 and IL­12 signaling. Common TYK2 variants are 
also associated with Crohn’s disease28 and psoriasis29. A different, rare 
TYK2 variant, rs34536443, is associated with multiple sclerosis30. IL­6 
signaling through IL­6R has diverse proinflammatory effects. In com­
bination with transforming growth factor (TGF)­β, it influences the 
ratio of TH17 to regulatory T (Treg) cells, promoting the differentiation 
of TH17 cells from naive T cells and inhibiting TGF­β–induced differ­
entiation into Treg cells31. Previous studies have reported no increase 
in TH17 lymphocyte counts in ankylosing spondylitis, suggesting that 
the IL6R association with ankylosing spondylitis operates through 
mechanisms other than effects on TH17 lymphocytes32,33. Whether 
IL­6 has a role in the differentiation or activation of non­canonical 
cellular sources of IL­17 such as γδ T cells, NK cells, neutrophils and 
mast cells, which have been implicated in ankylosing spondylitis, is 
unclear. IL­27 potentiates the differentiation of CD4+ TH1 cells, while 
suppressing the differentiation of T helper 2 (TH2) and TH17 cells. 
IL27 has previously been associated with both Crohn’s disease and 
type 1 diabetes (Supplementary Table 8), with the association in type 
1 diabetes being in the opposite direction to that observed in both 
ankylosing spondylitis and Crohn’s disease.
At IL23R, we identified rare variant associations with ankylosing 
spondylitis in addition to the two known common variant haplotypes 
at this locus. Although one of these haplotypes has been shown to 
be due to association with the rs11209026 coding SNP6,25, it is not 
clear from these genetic studies whether the second haplotype tagged 
by the intergenic SNP rs12141575 influences ankylosing spondylitis 
through effects on IL23R or IL12RB2. IL12RB2 encodes one of the 
two subunits of IL­12R, the stimulation of which drives CD4+ lym­
phocyte differentiation toward the TH1 lineage and away from the 
TH17 lymphocyte phenotype.
We identified six ankylosing spondylitis–associated genes that 
were also associated either with variation in CD8+ lymphocyte counts 
(EOMES, IL7R, RUNX3 and ZMIZ1) or CD4+ lymphocyte counts 
(BACH2 and SH2B3). EOMES encodes eomesodermin, a transcrip­
tion factor involved in CD8+ T cell differentiation whose expression is 
induced by RUNX3 (refs. 34–36). Where eomesodermin is deficient, 
CD8+ T cells have been shown to express IL­17 (ref. 37). IL­7 acts 
through IL­7R to induce RUNX3 expression in developing T cells, in 
turn favoring differentiation toward the CD8+ T cell lineage38. ZMIZ1 
is a transcriptional coactivator of the protein inhibitor of activated 
STAT (PIAS)­like family and thus may have effects on STAT­mediated 
cytokine signaling. ZMIZ1 has recently been shown to cooperate with 
activating NOTCH1 mutations in inducing T cell acute lymphoblastic 
leukemia, consistent with it having a role in T cell differentiation39. 
Whether these genes affect risk of ankylosing spondylitis directly 
through effects on CD8+ T cell differentiation is unclear. For example, 
although the risk haplotype at RUNX3 is associated with lower CD8+ 
T cell counts, at IL7R, the opposite phenotype is observed, suggesting 
that the mechanisms involved are more complex than a simple effect on 
CD8+ T cell counts. IL­7 treatment has been shown to increase TH17 
lymphocyte counts, and it may be that the association of IL7R with 
ankylosing spondylitis operates directly through such an effect40.
One of the genes associated with both ankylosing spondylitis and 
CD4+ lymphocyte counts, BACH2, encodes a B cell–specific transcrip­
tion factor with diverse effects on B cell differentiation and function41; 
association of ankylosing spondylitis with CD4+ lymphocyte counts 
may thus be an indirect effect mediated by B cells. This is particu­
larly noteworthy given the recent evidence suggesting that rituximab, 
a B cell–targeted therapy, may have beneficial effects in ankylosing 
spondylitis42. SH2B3 (also known as LNK) encodes an adaptor pro­
tein involved in T cell receptor signaling43. CD8+ lymphocytes are 
activated by the interaction of MHC class I peptides with their T cell 
receptors and may in turn become cytotoxic or memory T cells.
The association of four aminopeptidases involved in peptide trim­
ming before HLA class I presentation is particularly noteworthy. We 
have shown here and previously that genetic variants associated with 
reduced function of ERAP1 and loss of expression of ERAP2 are pro­
tective for ankylosing spondylitis. Whether LNPEP is also involved is 
uncertain, and identification of the key associated variants at NPEPPS 
will require further studies. It is possible that these genes operate in 
ankylosing spondylitis through a quantitative effect on HLA class I 
peptide presentation or a qualitative effect on the peptide reper­
toire presented. Downregulation of ERAP1 (refs. 44,45) and ERAP2 
(ref. 19) expression has been shown to reduce cell surface expression 
of HLA class I molecules. ERAP1 preferentially cleaves hydrophobic 
amino acids, whereas ERAP2 preferentially cleaves basic residues. 
ERAP1­ERAP2 heterodimers may thus act in concert, particularly in 
cleaving longer peptides45. It has been suggested that misfolding of 
nascent HLA­B*27 in the ER, leading to ER stress, may be involved in 
the pathogenesis of ankylosing spondylitis46. It is also possible that, 
by influencing the quantity of peptide available during HLA­B*27 
folding, ERAP1 and ERAP2 variants associated with disease risk slow 
the rate of this folding, thereby increasing ER stress.
In this study, over one­third of loci with common variant associa­
tions were found to harbor more than one disease­associated haplo­
type. Identifying these additional haplotypes increased the proportion 
of genetic variance explained in ankylosing spondylitis and, more 
notably, led to valuable biological insights. For example, association 
of ankylosing spondylitis with SNPs on chromosome 12p13 has previ­
ously been reported, although it was not clear whether the association 
was primarily with TNFRSF1A or LTBR, both plausible candidate 
genes6,7,47. The current study shows that there are two signals at this 
locus, one in TNFRSF1A and the other in LTBR. The primary associ­
ated SNP at TNFRSF1A (rs1860545) is in strong LD with a multiple 
sclerosis–associated SNP, rs1800696 (r2 = 0.96, D′ = 0.98) but with the 
opposite direction of association. rs1800696 has recently been shown 
to lead to the splicing out of exon 6 of TNFR1, resulting in loss of 
the transmembrane domain48. The resulting protein acts as a soluble 
decoy receptor for TNF, akin to the TNF inhibitor drug etanercept. 
TNF inhibitors are highly effective therapeutic drugs in ankylosing 
spondylitis, but their use can lead to induction or exacerbation of 
multiple sclerosis. The association with ankylosing spondylitis sug­
gests the possibility that disease activity and response to TNF inhibi­
tor therapy may be affected by this SNP.
Comparison of the genetic associations of ankylosing spondylitis 
with other diseases reinforces the considerable overlap with Crohn’s 
disease, ulcerative colitis and ankylosing spondylitis. Ankylosing 
spondylitis frequently complicates inflammatory bowel disease 
(both Crohn’s disease and ulcerative colitis), and increased cofamili­
ality with inflammatory bowel disease has been demonstrated49,50, 
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 suggesting shared etiopathogenesis. Overlapping genetic susceptibil­
ity between ankylosing spondylitis and inflammatory bowel disease 
has previously been reported51,52. The genes involved include many 
with effects on the IL­23 pathway, supporting the notion of this being 
a key pathway in the pathogenesis of these conditions, most likely 
through effects on gut mucosal immunology. However, the major loci 
for each disease are not shared, with ankylosing spondylitis showing 
no association with NOD2 or ATG16L1 and neither Crohn’s disease 
nor ulcerative colitis showing association with HLA-B*27. This sug­
gests that these disease­specific loci contribute to the organ and tissue 
specificity of the diseases with which they are associated, whereas 
the IL­23 pathway is involved in the core immunological pathway 
underlying all these conditions.
We also identified associations with three loci encoding G protein–
coupled receptors, including GPR35, GPR37 and GPR65, and a fourth 
(GPR25) is close to KIF21B, an established ankylosing spondylitis 
locus where the key associated variants are not yet defined. The func­
tions of these genes and their ligands are not well established. GPR35 
is reported to act as a receptor for 2­acyl lysophosphatidic acid, and 
GPR65 is reported to be a receptor for glycosphingolipids and pro­
tons; the ligands for GPR25 and GPR37 are not known. GPR65 has 
previously been associated with Crohn’s disease53 and multiple sclero­
sis54. The mouse homolog of GPR65, T cell death–associated gene 8, 
inhibits proinflammatory cytokine production (including of TNF­α 
and IL­6) in acidic conditions55, suggesting a potential mechanism 
in diverse autoimmune diseases. However, it also has anti­apoptotic 
effects and an ability to activate not only cyclic AMP (cAMP) intracel­
lular signaling but also other pathways, including mitogen­activated 
protein kinase (MAPK) and MEK/ERK signaling and thus is likely to 
have multiple functions56. Further research is needed into the func­
tions of these genes and their roles in autoimmune diseases.
It has long been suspected that associations in the MHC region 
with ankylosing spondylitis are not completely explained by 
HLA-B*27. The association of HLA-A*0201 with ankylosing 
 spondylitis at genome­wide significance in both HLA-B*27–positive 
and HLA-B*27–negative cases confirms that suspicion. HLA-A*02 
has previously been reported to be associated with anterior uveitis 
complicating ankylosing spondylitis57 and is a risk factor for vitiligo58. 
HLA-A*0201 has a protective effect in multiple sclerosis54 and is a risk 
allele for type 1 diabetes59, but no HLA-A association has previously 
been reported with ankylosing spondylitis itself.
In conclusion, we have increased the number of ankylosing spond­
ylitis–associated loci to 31, identifying 13 new loci and 12 additional 
ankylosing spondylitis–associated haplotypes at 11 loci, bringing the 
total number of genetic signals independently associated with anky­
losing spondylitis to 43. These loci reinforce the mounting evidence 
that aberrant peptide processing before MHC class I presentation and 
alterations of the IL­23 pathway are key elements in the pathogenesis 
of ankylosing spondylitis.
URL. Haploxt, http://genome.sph.umich.edu/wiki/Haploxt.
METHODS
Methods and any associated references are available in the online 
version of the paper.
Note: Supplementary information is available in the online version of the paper.
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ONLINE	METHODS
Samples. All cases had definite ankylosing spondylitis according to the modi­
fied New York criteria60. Written informed consent was obtained from all cases 
with approval from the relevant research ethics authorities at each participating 
center. A total of 12,252 DNA samples passed genotyping control filters. The 
case collection consisted of 10,417 individuals of European ancestry, 1,560 of 
Asian ancestry and 275 from Latin America (Colombia and Mexico). Of these, 
2,425 cases of European ancestry have previously been reported in GWAS.
We obtained 12,338 controls of European ancestry, 1,570 of East Asian 
ancestry and 445 from Latin America. These included shared controls from 
the UK 1958 Birth Cohort, the UK Blood Services Common Controls and the 
United States and from participating centers from France, The Netherlands, 
Norway, Spain, Mexico, Colombia, China, Taiwan and Korea.
Genotyping. Samples were genotyped using the Immunochip, an Illumina 
Infinium platform, according to the manufacturer’s recommendations. 
Control samples from the UK were genotyped at the Sanger Centre (Hinxton, 
Cambridge, UK) and at the University of Virginia (Charlottesville, Virginia, 
USA), control samples from the United States were genotyped at the Feinstein 
Institute (New York, New York, USA), and all other controls and all cases were 
genotyped at the University of Queensland Diamantina Institute (Brisbane, 
Queensland, Australia). Bead intensity data were processed and normalized 
for each sample in GenomeStudio; data for successfully genotyped samples 
were extracted, and genotypes were called within collections using optiCall61. 
NCBI Build 36 (hg18) mapping was used (Illumina manifest file Immuno_
BeadChip_11419691_B.bpm).
SNPs rs4552569, rs13210693 and rs17095830 were genotyped in 2,998 East 
Asian cases and 5,547 East Asian controls using TaqMan probes according to 
the manufacturer’s instructions.
The genotyping accuracy of seven disease­associated SNPs with MAF < 1% 
was confirmed by custom TaqMan genotyping assays. Taking into considera­
tion the five successfully developed assays, genotypes were completely con­
cordant with Immunochip genotyping. Assays could not be developed for 
two SNPs (rs280518 in TYK2 and rs75430612 in IL2R2). However, given the 
clean clustering achieved for these SNPs in microarray genotyping and the 
fact that they had previously been reported, it is likely that they represent 
true positives.
Data quality control. We first excluded, for each of the collections separately, 
SNPs with call rate below 95% or with a Hardy­Weinberg equilibrium P value 
of <1 × 10−6 in controls, as well as samples with call rate below 95%. For the 
overlapping SNPs, we performed pairwise missingness tests between the col­
lections and removed all SNPs with differential missingness (P < 1 × 10−7). 
After merging data sets, SNPs with call rate below 98% and samples with call 
rate below 98% were removed. A total of 128,935 SNPs were analyzed. Cluster 
plots were visually inspected for all SNPs used to inform conclusions.
The origins of samples of European and Asian ancestry were confirmed by 
principal­component analysis. Immunochip data were merged with genotype 
information from seven HapMap 3 populations (CEU, TSI, YRI, MEX, JPT, 
CHD and CHB), and samples were identified as European or East Asian on 
the basis of their projection onto the first five principal components of genetic 
variation (Supplementary Figs. 10–12). Ancestry outliers were removed by 
assigning samples to an ancestry group using a model­based unsupervised 
clustering approach62. A second round of principal­component analysis was 
performed on the European and Asian populations independently to better 
resolve ancestry differences within the cohorts. In both cases, only the first 
principal component was correlated with the places of origin of the samples, 
and only in the European collection was the principal component marginally 
correlated with case­control status (P = 0.016). The projection of the samples 
analyzed onto the first two principal components is shown in Supplementary 
Figures 3 and 4.
Duplicated samples (intentional or unintentional) and those showing 
cryptic relatedness were assessed for the European and Asian cohorts sepa­
rately by calculating identity by descent using PLINK (v1.07)63. For each pair 
of related samples (PI_HAT > 0.2), the sample with the lower call rate was 
removed, and, where the pair involved a case and a control with similar call 
rates (both above 98%), cases were preferentially selected for inclusion.
Association analysis. Association analysis and population stratification con­
trol was performed using linear mixed models as implemented in FaST­LMM 
(v1.05)64. For each chromosome, a relationship matrix was constructed with 
all SNPs, excluding those in the chromosome being analyzed and in the MHC 
region. Conditional analysis for secondary signal detection was performed by 
fitting the primary SNP as a fixed effect as implemented in FaST­LMM and 
using the same SNP set for the relationship matrix.
The decision to apply linear mixed models rather than principal­component 
analysis for population stratification was informed by a comparison of 
logistic regression with principal components as covariates against linear 
mixed models, including different strategies for computing the kinship (or 
similarity) matrix. In this analysis, we concluded that linear mixed models, 
when using a kinship matrix, outperformed logistic regression with principal 
components as covariates, as assessed by the genomic inflation factor in all 
SNPs (data not shown). We also noticed that including all SNPs when comput­
ing the kinship matrix resulted in further loss of power, particularly matrices 
calculated including HLA-B*27–tagging SNPs, which are a good proxy for 
phenotype status in a case­control study such as ours. Thus, including SNPs 
tagging HLA-B*27 in the kinship matrix would have the effect of controlling 
for affected status, reducing statistical power in a case­control study.
Transformation of SNP effects from the linear 0–1 scale to the liability 
scale is described in the Supplementary Note. Association plots were gener­
ated using LocusZoom, with recombination rates estimated from the HapMap 
CEU panel (Utah residents of Northern and Western European ancestry) and 
pairwise LD r2 values estimated from the set of control samples65.
Low-frequency SNP association analysis. A collection of 7,447 cases and 
11,479 controls were selected for low­frequency SNP association analysis. 
These samples were of UK European origin according to principal­component 
analysis (Supplementary Fig. 11) and recruitment center informaiton. 
Association analysis was performed with Fisher’s exact test and with logistic 
regression conditioning on common variant association within the locus.
Imputation. We imputed genotypes in candidate regions for the European 
and Asian cohorts using the EUR and ASN reference panels, respectively, from 
the 1000 Genomes Project (Phase 1, 2010–2011 data freeze)66. Genotype data 
were phased with MACH, and genotypes were imputed with Minimac67. SNPs 
with low imputation quality (r2 < 0.5) were excluded. Association analysis in 
imputed genotypes was assessed with probabilistic genotypes, correcting for 
population stratification with the first five principal components as covariates, 
using logistic regression as implemented in mach2dat.
HLA-B*27–tagging SNP. Imputed SNPs in the MHC region were tested 
for association and for tagging of HLA-B*27. Performance as a tagging SNP 
was assessed with a cohort of samples previously genotyped at this locus 
(Supplementary Table 6b), including 754 controls from the 1958 Birth Cohort 
population68, 542 ankylosing spondylitis cases from the UK and Australia and 
104 ankylosing spondylitis cases and 5 controls from China. SNP rs116488202 
was used to tag HLA-B*27 in all analyses.
Overlap with other autoimmune diseases. For all genome­wide significant and 
suggestive loci for ankylosing spondylitis susceptibility, we searched in a chromo­
somal window of 0.5 cM around the lead SNP for associations with other autoim­
mune diseases in the National Human Genome Research Institute (NHGRI) 
GWAS catalog (accessed 5 June 2012). We then computed the LD between the 
ankylosing spondylitis–associated SNP and the reported SNP using phased data 
from the 1000 Genomes Project. If the ankylosing spondylitis–associated SNP 
was not found, we searched for the next most significant SNP in the locus. When 
a pair of SNPs was in LD (either r2 > 0.40 or D′ > 0.40), a connection between the 
two diseases was noted. Positively correlated alleles were then compared for their 
risk or protective effect on the two diseases to determine whether the directionali­
ties of effect were concordant or discordant. LD was computed with Haploxt.
HLA-B*27 experiment-wide interactions. Testing for interaction between 
HLA-B*27–tagging SNP rs116488202 and all other non­MHC SNPs was 
performed in samples of European ancestry by logistic regression fitting a 
dominant term for the HLA-B*27–tagging SNP and an additive term for each 
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test SNP, including a multiplicative interaction term, and five principal com­
ponents for ancestry correction:
y x x x x i i
i
= + + + × +
=
∑b b b b b0 1 1 2 2 12 1 2
1
5
PC PC
where y is the log odds of disease, βo is the intercept, x1 is a SNP variable 
reflecting an HLA-B*27 dominant effect (0 or 1), x2 is a SNP variable coded 
to reflect an underlying additive effect (0, 1 or 2), PCi codes for the projec­
tion of samples onto the ith principal component and β terms are regression 
coefficients estimated from the data.
CD4+ lymphocyte counts in ankylosing spondylitis cases and controls. 
Peripheral blood was obtained from 20 individuals with active ankylosing spond­
ylitis (erythrocyte sedimentation rate of >25 mm/h and CRP concentration of 
>10 mg/l) who were naive for TNF inhibitor and 20 age­matched healthy con­
trols. Peripheral blood mononuclear cells (PBMCs) were extracted using standard 
density gradient centrifugation over Ficoll­Paque Plus (GE Healthcare). Extracted 
PBMCs were frozen in FBS with 10% DMSO until needed. Frozen PBMCs were 
thawed into RPMI supplemented with 20% FBS and were washed once in RPMI 
supplemented with 10% FBS. Cells were rested in RPMI supplemented with 
10% FBS for approximately 1 h at 37 °C at 5% CO2 before further use. Cells 
were stained with CD3 ECD (UCHT1, Beckman Coulter) and CD4 Pacific Blue 
(13B8.2, Beckman Coulter). Antibodies were used at final dilutions of 1:100 of 
antibody stocks. Dead cells were excluded using a Live/Dead Fixable Dead Cell 
Stain kit (Invitrogen). Cells were acquired on a Gallios flow cytometer (Beckman 
Coulter), and staining was analyzed using Kaluza software (Beckman Coulter).
IL-6R measurements in serum. Serum was collected from ankylosing spond­
ylitis cases and controls of European ancestry attending the Princess Alexandra 
Hospital Brisbane Ankylosing Spondylitis Specialist Clinic who were either 
homozygous for the T or C allele of rs4129267. Serum concentrations of IL­6R 
were measured using an IL­6R Quantikine ELISA (R&D Systems), and optical 
density (OD) was determined on a Synergy 2 Microplate reader (BioTek). 
Serum was diluted 1:100, and ELISAs were performed according to the 
manufacturer’s instructions. All data shown in graphs represent mean ± s.e.m., 
and differences between groups were analyzed using non­parametric one­way 
ANOVA; Kruskal­Wallis test with Dunn’s multiple­comparison post­hoc 
test in GraphPad Prism 5 software. Statistical significance was accepted at a 
significance level of P < 0.05.
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